Unsurprisingly, compared to the control group, the AMD group had significantly lower mean visual acuity (p-value < 0.0001), a higher mean central macular thickness (CMT) at the time of the initial diagnosis (p-value < 0.0001) and a lower mean CMT at the time of inclusion after the anti-VEGF injections (p-value = 0.024). The gene discussed is VEGFA; the disease is age-related macular degeneration.